USA flag logo/image

An Official Website of the United States Government

Miniaturized Distal Vibration System for Penetration of Vascular Occlusions

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
96308
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
HL097441
Solicitation Year:
N/A
Solicitation Topic Code:
NHLBI
Solicitation Number:
N/A
Small Business Information
FRANTZ MEDICAL DEVELOPMENT, LTD
7740 METRIC DRIVE MENTOR, OH 44060
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: Miniaturized Distal Vibration System for Penetration of Vascular Occlusions
Agency: HHS
Contract: 1R43HL097441-01A1
Award Amount: $100,121.00
 

Abstract:

DESCRIPTION (provided by applicant): Chronic total occlusions (CTOs), defined as vessels that have been completely occluded for 3 months, are a prevalent vascular disease found in about one-third of patients undergoing a coronary angiogram and in 30-50% of peripheral procedures. Revascularization of CTOs offers important benefits to the patient including reduced angina symptoms, improved left ventricular function, reduced need for Coronary Artery Bypass Graft (CABG), and a lower incidence of death or Myocar dial Infarction (MI), but success rates are still considerably low. Inability to cross a CTO with a guide wire is by far the leading cause of failed CTO revascularization attempts (89% of cases in some studies), thus medical device makers have focused on i mproving cross rates via two strategies: specialized CTO wires and dedicated CTO devices. However, these new devices have either resulted in increased risk of perforation and dissection of the vessel or have had marginal improvements in CTO penetration. Th erefore, there is still an unmet need for an active CTO device that is safe, highly effective at tunneling through CTOs, and augments the use of a conventional guide wire - the workhorse device of intervention lists. Frantz Medical Development (FMD) has id entified a solution to this unmet need: a miniaturized electromagnetic engine incorporated into the distal end of a vascular guide wire and catheter combination. The engine is constructed by fixing a series of spaced magnetic beads to a guide wire and outf itting the catheter with a corresponding set of coil segments. Driving the coils with alternating current produces an alternating magnetic field, which acts on the magnets to vibrate the guide wire. The vibrations at the guide wire tip provide additional p enetrating force for active penetration through CTOs. Users can activate the vibrations anytime additional penetrating power is desired, and then switch off the system to return to a passive guide wire that retains the same feel and handling characteristic s of a traditional wire. Based on encouraging feasibility results, FMD has prepared this proposal describing the goals and strategy of Phase I, Concept Development. By the completion of Phase I, FMD will have built 3rd Generation prototypes of the VTG Syst em and used them for validating the safety, efficacy, and usability of the technology for crossing refractory CTOs. The 3rd Generation design will be scaled down to final size and will incorporate various other performance improvements. The final scale pro totypes will then be used for fine tuning the operating parameters and for confirming the safety, efficacy, and usability of the device, both on the bench and in an in vivo animal study. In addition, FMD will have established a clear path through the next phases of development and commercialization. PUBLIC HEALTH RELEVANCE: Angioplasty, a minimally invasive catheterization procedure that opens a blocked coronary or peripheral vessel with a balloon and commonly a stent, has improved the outcome of pat ients with vascular disease. Our vibration guide wire platform technology will improve angioplasty of chronic blockages ( Chronic Total Occlusions ) while maintaining the safety of these procedures, ultimately increasing the number of patients with chronic occlusions that can be safely treated with angioplasty.

Principal Investigator:

Stephanie A. Harrington
4402551155
SHARRINGTON@FRANTZGROUP.COM

Business Contact:

Stephanie A. Harrington
sharrington@frantzgroup.com
Small Business Information at Submission:

FRANTZ MEDICAL DEVELOPMENT, LTD
7740 METRIC DRIVE MENTOR, OH 44060

EIN/Tax ID: 113301428
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No